Blood-borne Assessment of Stromal Activation in Esophageal Adenocarcinoma to Guide Tocilizumab Therapy

Esophageal Adenocarcinoma Clinical Trial

— BASALT  

Official title:

Blood-borne Assessment of Stromal Activation in Esophageal Adenocarcinoma to Guide Tocilizumab Therapy: a Randomized Phase II Proof-of-concept Study

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04554771
• Other study ID #: NL74310.018.20
• Secondary ID: 2020-002909-25
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: January 27, 2021
• Est. completion date: January 1, 2024

Study information

• Verified date: December 2022
• Source: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to demonstrate that stroma-targeting by tocilizumab in patients with adenocarcinoma of the esophagus or gastroesophageal junction with highly activated stroma increases efficacy of chemoradiotherapy measured by pathological response according to the Mandard criteria. Patients will be grouped for ADAM12, a non-invasive blood-borne marker of stromal activation.

Description:

Randomized phase II proof-of-concept study with tocilizumab and standard of care paclitaxel, carboplatin and radiation followed by surgical resection of the oesophagus for patients with surgically resectable adenocarcinomas of the oesophagus or oesophageal junction. Patients will be grouped for serum ADAM12 with a cutoff of 203 ng/mL. Patients in both groups will be randomized to receive tocilizumab 8mg/kg on day 1, 15 and 29 or not in addition to paclitaxel 50mg/m2, carboplatin dosed with area under the curve (AUC) 2 on day 1, 8, 15, 22 and 29 and radiation 41.4 Gy in 23 fractions. Surgery will be planned approximately in week 13-15, which is 8 to 10 weeks after the end of chemoradiation.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 41
• Est. completion date: January 1, 2024
• Est. primary completion date: May 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically proven adenocarcinoma of the esophagus or gastroesophageal junction.

• Surgical resectable (<T4b, N0 or N+, M0), as determined by Endoscopic UltraSound (EUS) and/or CT scan of neck, thorax and abdomen. Tumors that cannot be passed with an endoscope for endoscopic ultrasound are eligible if all other criteria are fulfilled.

• T1N+ tumors are eligible.

• Tumor length longitudinal = 10 cm; if larger than 10 cm, inclusion should be discussed with the principal investigator.

• If the tumor extends below the gastroesophageal (GE) junction into the proximal stomach, the bulk of the tumor must involve the esophagus or GE junction.

• Age = 18.

• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

• Adequate hematological, renal and hepatic functions defined as:

• neutrophiles = 1.5 x 109/L

• platelets = 100 x 109/L

• hemoglobin = 5.6 mmol

• total bilirubin = 1.5 x upper normal limit

• creatinine clearance (Cockroft) > 60 ml/min

• Written, voluntary informed consent

• Patients must be accessible to follow up and management in the treatment center

Exclusion Criteria:

• Past (within 5 years) or current history of malignancy other than entry diagnosis interfering with prognosis of esophageal cancer, not including superficial and adequately treated skin and cervical malignancies.

• Previous chemotherapy, radiotherapy and/or treatment with Interleukin-6 (IL6) receptor blockers for esophageal cancer

• Previous radiation to the mediastinum precluding full dose radiation of the currently present esophageal tumor.

• Previous chemotherapy and/or treatment with targeted agents and/or IL6 receptor blockers for other forms of cancer within the last six months.

• Invasion of the tracheobronchial tree or presence of tracheoesophageal fistula.

• T1N0 tumors or in situ carcinoma.

• Pregnancy (positive serum pregnancy test), planning to become pregnant, and lactation.

• Patient (male or female) is not willing to use highly effective methods of contraception (per institutional standard) during treatment and for 6 months (male or female) after the end of treatment.

• Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) precluding major surgery.

• Pulmonary fibrosis and/or severely impaired lung function precluding major surgery.

• Serious underlying medical condition which would impair the ability of the patient to receive the planned treatment, including prior allergic reactions to drugs containing Cremophor, such as teniposide or cyclosporine.

• Dementia or altered mental status that would prohibit the understanding and giving of informed consent

• Inadequate caloric- and/or fluid intake despite consultation of a dietician and/or tube feeding.

• Requires systemic treatment with IL6 receptor blockers or IL-6 antagonists, Tumor Necrosis Factor (TNF)-alpha blockers or other biologicals within the last six months before the first dose of trial treatment.

• Has evidence of interstitial lung disease or active, non-infectious pneumonitis.

• Has an active infection requiring systemic therapy which has not resolved 3 days (simple infection such as cystitis) to 7 days (severe infection such as pyelonephritis) prior to the first dose of trial treatment.

• Has a total cholesterol > 6.5 mmol/L despite adequate treatment with lipid-lowering agents.

• Has evidence of (latent) tuberculosis infection in patient history.

• Receiving a live or live weakened vaccine during treatment with tocilizumab

• Has evidence of acute or chronic infection with hepatitis B

• Patients with prior allogeneic stem cell or solid organ transplantation.

• Pre-existing motor or sensory neurotoxicity greater than World Health Organization (WHO) grade 1.

• Known allergy for tocilizumab or one of its excipients (sucrose, polysorbate 80, disodium phosphate dodecahydrate, sodium dihydrogen phosphate dehydrate)

Related Conditions & MeSH terms

• Adenocarcinoma
• Esophageal Adenocarcinoma
• Esophageal Neoplasms
• Oesophageal Adenocarcinoma
• Resectable Carcinoma

Intervention

Drug:
• Tocilizumab 20 Mg/mL Intravenous Solution
tocilizumab 8 mg/kg with a maximum of 800 mg intravenously on day 1, 15 and 29 of standard of care neoadjuvant chemoradiation
• Paclitaxel
Paclitaxel 50 mg/m2 will be given intravenously on days 1, 8, 15, 22 and 29
• Carboplatin
Carboplatin AUC = 2 will be given intravenously on days 1, 8, 15, 22 and 29

Radiation:
• External beam radiotherapy
External beam radiotherapy will be delivered to a total dose of 41.4 Gy in 23 fractions of 1.8 Gy, 5 fractions per week starting the first day of the first cycle of chemotherapy

Locations

Country	Name	City	State
Netherlands	Academic Medical Center, Medical Oncology	Amsterdam

Sponsors (2)

Lead Sponsor	Collaborator
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	Noordwest Ziekenhuisgroep

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Predictive biomarkers using oa RNA sequencing	Exploratory objectives are to identify additional predictive biomarkers based on tumor, fecal and blood samples. Among others we will use RNA sequencing.	54 months
Primary	Efficacy defined as pathological response to chemoradiotherapy according to the Mandard criteria	The primary outcome is efficacy of tocilizumab in patients with high and low stroma activation defined as pathological response according to the Mandard criteria	34 months
Secondary	R0 resection rate	Percentage of R0 resection at surgery	34 months
Secondary	Progression free survival	Average time to progression of disease	34 months
Secondary	Overall survival	average time to date of death	34 months
Secondary	Interleukin 6- Signal Transducer and Activator of Transcription 3 (IL6-STAT3) pathway inhibition measured by gene expression analysis	Analysis of gene expression to measure level of inhibition of IL6-STAT3 pathway	36 months
Secondary	IL6-STAT3 pathway inhibition measured by immunohistochemistry	Phosphorylated STAT3 and stromal abundance measured by immunohistochemistry in formalin-fixed paraffin-embedded tumor tissue	36 months
Secondary	Levels of ADAM12 in tumor biopsies and serum	average levels of ADAM12 in tumor biopsies and serum	36 months
Secondary	Incidence and severity of toxicity	Incidence of treatment-emergent adverse events according to CTCAE v5.0	34 months
Secondary	Incidence and severity of radiation toxicity	Incidence of treatment-emergent adverse events according to Radiation Oncology Group (RTOG) criteria	34 months
Secondary	Incidence and severity of post-operative complications	Incidence and severity of post-operative complications according to the Clavien - Dindo classification	36 months
Secondary	Feasibility completion	Percentage completion of chemotherapy and radiation treatment	34 months
Secondary	Feasibility withdrawal rate	Percentage withdrawal rate from surgery due to tocilizumab related complications	34 months
Secondary	Feasibility delay	Percentage delay of surgery due to tocilizumab related complications	36 months